Eli Lilly Receives Positive EU Recommendation for Oral Weight-Loss Drug Foundayo

Key Facts

Eli Lilly received a positive recommendation from EU regulators for its new oral weight-loss drug, Foundayo. Seeking Alpha reported that a committee of the European Medicines Agency issued a positive opinion for marketing authorization, representing a key step toward full approval within the European Union.

The regulatory backing follows clinical data supporting the efficacy of the oral pill, which offers a more convenient alternative to injectable treatments in the competitive obesity market. LLY closed at $1251.61 on October 15, 2026, after reaching a session high of $1275.88.